Shares of Dr. Reddy’s Laboratories were upbeat on Monday after a report from CNBC-TV18 said that the pharma firm was taking part in the bidding process to acquire Novartis AG’s stake in Novartis India.

What Happened: During recent earnings calls, the leadership at Dr. Reddy’s has hinted at their keenness to explore opportunities for acquiring portfolios with a domestic focus.

Swiss pharmaceutical titan Novartis AG kickstarted a strategic evaluation of its subsidiary, Novartis India, on February 16. This strategic review encompasses Novartis AG’s 70.68% shareholding in its Indian unit.

See Also: Paytm’s Share Price Hit Upper Circuit For 2nd Straight Session: What Brokerages Say Could Happen Next

Why It Makes Sense: Dr. Reddy’s has a history of engaging in strategic collaborations with Novartis India. Notably, in February 2022, Dr. Reddy’s inked an exclusive agreement for sales and distribution with Novartis, encompassing a range of medications including Voveran, Calcium range and Methergine. Subsequently, in April of the same year, Dr. Reddy’s acquired Novartis India’s Cidmus brand.

With the existing distribution agreement already enveloping a significant portion of Novartis India’s product portfolio, covering nearly 50% of its sales, brokerage firm Nomura believes Dr. Reddy’s is ideally positioned to acquire Novartis AG’s stake in its Indian subsidiary.

Having successfully launched several of its own brands in the domestic market last year, Dr. Reddy’s is now strategically focused on leveraging inorganic opportunities to drive its next phase of growth.

Price Action: Dr. Reddy’s Laboratories’ share price was up 1.68% at ₹6,423 in the afternoon session of trade on Monday.

Read Next: Pakistan’s Entire GDP Now Stands $20B Below Tata Group’s Market Cap